Last reviewed · How we verify
Oral Captopril
Oral Captopril is a ACE inhibitor Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Hypertension, Heart failure, Post-myocardial infarction left ventricular dysfunction.
Captopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.
Captopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction left ventricular dysfunction.
At a glance
| Generic name | Oral Captopril |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Captopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing angiotensin II levels, the drug causes vasodilation, decreases peripheral vascular resistance, and reduces aldosterone secretion, leading to lower blood pressure and reduced cardiac workload. This mechanism also provides cardioprotective and renoprotective effects.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction left ventricular dysfunction
- Diabetic nephropathy
Common side effects
- Dry cough
- Dizziness
- Hyperkalemia
- Angioedema
- Hypotension
- Taste disturbance
Key clinical trials
- The Use of Virtual Reality and Music Therapy for Hypertensive Urgency (NA)
- Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease (EARLY_PHASE1)
- Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
- Cardioprotection on Chemotherapy-Induced Cardiotoxicity (PHASE3)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Primary Aldosteronism LC-MS/MS-specific Cutoffs
- The Plasma Metabolomics Profiling of Primary Aldosteronism
- Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Captopril CI brief — competitive landscape report
- Oral Captopril updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Oral Captopril
What is Oral Captopril?
How does Oral Captopril work?
What is Oral Captopril used for?
Who makes Oral Captopril?
What drug class is Oral Captopril in?
What development phase is Oral Captopril in?
What are the side effects of Oral Captopril?
What does Oral Captopril target?
Related
- Drug class: All ACE inhibitor drugs
- Target: All drugs targeting Angiotensin-converting enzyme (ACE)
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
- Indication: Drugs for Post-myocardial infarction left ventricular dysfunction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing